The Schroder UK Public Private Trust could finally see a positive re-rating, having been "left behind" despite a rally in funds investing heavily into the Covid-19 tech and healthcare boom, according to analysts at Stifel.
Investors in the trust, formerly Woodford Patient Capital, have had a rough ride since the company floated on the stockmarket. Shares have lost 70% on their IPO price and 75% since their 119p peak five years ago, having become embroiled in the liquidity crisis at the ill-fated Woodford Investment Management. Schroders took over the trust in December 2019, with fund buyers welcoming the move. Managers Ben Wicks and Tim Creed have been quick to outline their intentions as they look to turn the vehicle's fortunes around. Buyers back ex-Woodford trust as Schroders sets out short- and long...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
